Attached files
file | filename |
---|---|
EX-10.1 - EXHIBIT 10.1 - BIOMIMETIC THERAPEUTICS, INC. | v303741_ex10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
February 21, 2012
BIOMIMETIC THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | 000-51934 | 62-1786244 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
389 Nichol Mill Lane, Franklin, Tennessee 37067
(Address of Principal Executive Offices) (Zip Code)
(615) 844-1280
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 | Entry into a Material Definitive Agreement. |
On February 21, 2012, BioMimetic Therapeutics, Inc. (the “Company”) and Novartis Vaccines and Diagnostics, Inc. (“Novartis”) entered into an amendment (the “Amendment”) to the Amended and Restated Manufacturing and Supply Agreement, effective December 1, 2009, between the Company and Novartis (the “Agreement”). The Amendment is deemed to be effective as of January 1, 2012.
Under the Amendment, the Company’s obligations to purchase certain minimum quantities of rhPDGF-BB from Novartis have been modified, the parties adjusted the minimum shelf life requirement of rhPDGF-BB delivered to the Company’s designated carrier and the parties agreed to bear their own costs associated with qualifying and licensing certain drug substance transfer changes. Additionally, the parties amended certain other compensation terms included in the Agreement.
The foregoing description of the Amendment is only a summary and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and which is incorporated by reference into this Item 1.01.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
10.1 Amendment, effective January 1, 2010, to Amended and Restated Manufacturing and Supply Agreement, effective December 1, 2009, between BioMimetic Therapeutics, Inc. and Novartis Vaccines and Diagnostics, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOMIMETIC THERAPEUTICS, INC. | ||
By: | /s/ Earl Douglas | |
Name: Earl Douglas | ||
Title: General Counsel |
Date: February 27, 2012